FDA
-
-
-
-
-
-
-
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
-
-
-
-
-
-
-
Oppenheimer Defending Trevi Therapeutics (TRVI) Amid 10% drop: 'We would buy today's weakness'
-
-
-
-
-
-
-
Trevi Therapeutics schedules FDA meeting for chronic cough drug program
-
-
-
-
-
-
-
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
-
-
-
-
-
-
-
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
-
-
-
-
-
-
-
Trevi Therapeutics (TRVI) Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
-
-
-
-
-
-
-
Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update
-
327,801 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

